After years of accelerating progress, ALS research has reached a pivotal turning point—and Augie’s Quest to Cure ALS is making the next phase possible.
Scientific advances in genetics, biomarkers, disease biology, and technology have unlocked more promising therapeutic pathways than ever before. Yet without the right infrastructure and expertise, many of these breakthroughs risk slowing before they can reach patients.
Through the leadership and funding of Augie’s Quest, its research partner, ALS Therapy Development Institute, is purpose-built to meet this moment—transforming scientific potential into real-world progress.
Thanks to your past support of Augie’s Quest to Cure ALS, our research partner ALS TDI is built to address exactly this challenge, and Augie’s Quest is the catalyst to make this new path forward possible.
As one of the very few research labs in the world with deep expertise across every stage of ALS drug discovery–from early target discovery to cellular and animal models, biomarkers, and translational science–ALS TDI is uniquely equipped to rigorously test potential therapies and advance the strongest science toward trials.
Because of this integrated capability, ALS TDI plays a role in ALS research that extends well beyond their current internal programs. In addition to advancing therapies developed in the lab, they are increasingly called upon by academic and industry partners around the world to help evaluate and validate potential ALS treatments.
The ability to move seamlessly from early discovery through translational testing has made ALS TDI a critical hub for global ALS drug discovery, one of the few places where promising ideas can be tested rigorously, efficiently, and without silos.
As the pace of discovery continues to accelerate, the number of programs with potential to advance continues to grow.
With expanded facilities and a growing research team, Augie’s Quest is committed to increased funding allowing ALS TDI to:
- Accelerate drug discovery
Increase the speed and scale of therapeutic screening to advance promising treatments faster. - Move more therapies toward clinical trials
Generate the rigorous data and validation needed to support efficient progression to human testing. - Broaden and refine ALS models and tools
Develop more advanced disease models to support precise, targeted therapeutic strategies. - Advance more ideas in parallel
Pursue multiple therapeutic approaches at once—reducing risk and increasing the likelihood of meaningful breakthroughs.
Built by the Community. Designed for Impact.
This expansion is made possible by a generous commitment from Augie’s Quest to Cure ALS, along with the continued support of the ALS community, whose belief in urgency, rigor, and bold action has always powered our work.
Because of this support, ALS TDI is positioned to become the largest and most impactful ALS-focused drug discovery laboratory in the world, purpose-built to turn scientific opportunity into real treatments.
Augie’s Quest provided $3 million allowing ALS TDI to hire new scientists and build-out an expanded laboratory space at 200 Arsenal Yards Blvd. in Watertown, MA. Each step forward increases our ability to move faster, test smarter, and deliver answers that matter.
